Latest & greatest articles for adhd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adhd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adhd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

ADHD

ADHD (or Attention deficit hyperactivity disorder) is a neurodevelopmental type mental disorder. It is characterised two main categories of two types of behavioural problems:

  • inattentiveness
  • hyperactivity and impulsiveness

Most people with ADHD have problems that fall into both categories, but it doesn’t have to be the case. If a person just has inattentiveness it is referred to as attention deficit disorder (ADD).

Methylphenidate is a commonly used medication used to treat patients suffering from attention-deficit hyperactivity disorder. Methylphenidate is part of a group of drugs known as stimulants. Central nervous system stimulants help change the amounts of natural substances in the brain. But it is not the only intervention; others include Bupropion, exercise and CBT (Cognitive behavioural therapy).

Extensive ADHD research and case studies have been carried out over numerous years. Trip has unrivalled coverage of the evidence base including systematic reviews, clinical trials, clinical guidelines and case studies.

Studies are ongoing to assess the safety and effectiveness of stimulants used on children with ADHD and intellectual disabilities as well as in other populations and other interventions. Trip also includes ongoing controlled trials and ongoing systematic reviews (via the PROSPERO database).

Top results for adhd

181. CPG on Attention Deficit Hyperactivity Disorder (ADHD) in the Child and Adolescent Population

CPG on Attention Deficit Hyperactivity Disorder (ADHD) in the Child and Adolescent Population Clinical Practice Guideline on Attention De? cit Hyperactivity Disorder (ADHD) in Children and Adolescents CLINICAL PRACTICE GUIDELINES IN THE SPANISH NATIONAL HEALTHCARE SYSTEM MINISTRY OF HEALTH, SOCIAL POLICY , AND EQUALITY MINISTERIO DE SANIDAD, POLÍTICA SOCIAL E IGUALDADIt has been 5 years since the publication of this Clinical Practice Guideline and it is subject to updating. Clinical Practice (...) 11. Dissemination and implementation 169 12. Future research recommendations 171 It has been 5 years since the publication of this Clinical Practice Guideline and it is subject to updating. 6 CLINICAL PRACTICE GUIDELINE ON ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS Appendices Appendix 1 Levels of evidence and degrees of recommendation 176 Appendix 2 Diagnostic criteria for ADHD 177 Appendix 3 Information for patients, family members and educators 180 Appendix 4

2010 GuiaSalud

182. Review: ADHD impairs quality of life, but children and young people with ADHD perceive less impairment than parents

-Research Version, the Munich Quality of Life Questionnaire for Children, the Dutch Child AZL TNO Quality of Life, the TNO AZL Child Quality of Life, the EuroQoL Five-Dimension Questionnaire, standard gamble interviews and the Global Impression of Perceived Difficulties. The only disorder-specific measure used was the ADHD Impact Module. Methods Design: Systematic review. Data sources: Ovid MEDLINE (R), Cochrane database of systematic reviews, ACP Journal Club, DARE, CCTR, CMR, HTA, NHSEED, EMBASE (...) Review: ADHD impairs quality of life, but children and young people with ADHD perceive less impairment than parents Review: ADHD impairs quality of life, but children and young people with ADHD perceive less impairment than parents | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your

2010 Evidence-Based Mental Health

183. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis

Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

184. Girls with ADHD have an increased risk of psychopathology in young adulthood

is the prevalence of psychopathology in girls with and without attention-deficit hyperactivity disorder (ADHD) followed into young adulthood? Population: A total of 262 girls aged between 6 and 18 years were recruited from various from various psychiatric and paediatric sources. Out of these, 140 girls had DSM-III-R ADHD, and 122 did not (controls). Exclusion criteria: being adopted, nuclear family not available for participation, major sensorimotor disabilities, psychosis, autism, full-scale IQ<80 (...) , or inadequate ability with the English language. Setting: USA; time period not stated. Prognostic factors: Diagnosis of ADHD. Outcomes: Lifetime and previous-year DSM-IV psychopathology, including composite categories of antisocial disorders, mood disorders, anxiety disorders, developmental disorder, and substance-dependence disorders. Diagnoses were assessed in interviews with the participants and their mothers using the Structured Clinical Interview for DSM-IV and modules of the DSM-IV modified Schedule

2010 Evidence-Based Mental Health

185. Bupropion for adults with attention deficit hyperactivity disorder: a review of the clinical effectiveness and harms of misuse

health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Bupropion for adults with attention deficit hyperactivity disorder: a review of the clinical effectiveness and harms of misuse . Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2010 Authors' conclusions RCTs examining the efficacy of bupropion in adult ADHD frequently reported (...) Bupropion for adults with attention deficit hyperactivity disorder: a review of the clinical effectiveness and harms of misuse Bupropion for adults with attention deficit hyperactivity disorder: a review of the clinical effectiveness and harms of misuse Bupropion for adults with attention deficit hyperactivity disorder: a review of the clinical effectiveness and harms of misuse Canadian Agency for Drugs and Technologies in Health Record Status This is a bibliographic record of a published

2010 Health Technology Assessment (HTA) Database.

186. Early school-based screening and intervention programmes for ADHD did not improve children's outcomes at age 10

and intervention programmes for ADHD did not improve children's outcomes at age 10 Statistics from Altmetric.com Question Question How do early school-based screening and educational interventions affect the long-term outcomes for children at risk for attention deficit hyperactivity disorder (ADHD)? Patients 487 children (age 10–11) from 308 schools who had been screened for ADHD symptoms between 4 and 5 years of age. Initially 68 711 children aged 4–5 years old were screened in 2040 schools from 24 local (...) education authority (LEA) areas in England; 7570 children were identified as having high teacher-rated hyperactivity/inattention scores (six or more ADHD symptoms as defined in Diagnostic and Statistical Manual, Fourth Edition criteria). These schools were randomised to receive one of four interventions (see Intervention below). The current study asked a sample of 549 schools from the 20 LEA areas with ≥20 participating schools, and 1662 children (and their parents) from these schools to participate

2010 Evidence-Based Mental Health

187. Children with ADHD at increased risk of adolescent ADHD, ODD, anxiety or depression and functional impairment

risk of adolescent ADHD, ODD, anxiety or depression and functional impairment Statistics from Altmetric.com Question Question What are the adolescent outcomes of childhood attention-deficit hyperactivity disorder (ADHD)? Population 169 adolescents who had been identified as being at high risk of ADHD in childhood (94 met full Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) ADHD criteria, 75 met subthreshold criteria), and a matched group of 163 peers who had been (...) Children with ADHD at increased risk of adolescent ADHD, ODD, anxiety or depression and functional impairment Children with ADHD at increased risk of adolescent ADHD, ODD, anxiety or depression and functional impairment | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username

2010 Evidence-Based Mental Health

188. Lisdexamfetamine dimesylate - Attention deficit hyperactivity disorder

with other long acting agents. Background: Lisdexamfetamine is approved by Health Canada for the treatment of attention deficit hyperactivity disorder (ADHD) in children aged six to 12 years. It is a prodrug of dextroamphetamine. Following oral administration, lisdexamfetamine is rapidly absorbed in the gastrointestinal tract and converted to the active form, dextroamphetamine. The recommended starting dose of lisdexamfetamine is 30 mg daily with titration to a maximum of 50 mg daily. It is available (...) Lisdexamfetamine dimesylate - Attention deficit hyperactivity disorder Common Drug Review CEDAC Meeting – November 18, 2009 Page 1 of 5 Notice of CEDAC Final Recommendation – December 18, 2009 © 2009 CADTH CEDAC FINAL RECOMMENDATION LISDEXAMFETAMINE DIMESYLATE (Vyvanse – Shire Canada Inc.) Indication: Attention Deficit Hyperactivity Disorder Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that lisdexamfetamine not be listed. Reason for the Recommendation

2010 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

189. Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. Full Text available with Trip Pro

Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. Attention-deficit/hyperactivity disorder (ADHD) in adulthood is a prevalent, distressing, and impairing condition that is not fully treated by pharmacotherapy alone and lacks evidence-based psychosocial treatments.To test cognitive behavioral therapy for ADHD in adults treated with medication but who still have clinically significant (...) support (which is an attention-matched comparison).The primary measures were ADHD symptoms rated by an assessor (ADHD rating scale and Clinical Global Impression scale) at baseline, posttreatment, and at 6- and 12-month follow-up. The assessor was blinded to treatment condition assignment. The secondary outcome measure was self-report of ADHD symptoms.Cognitive behavioral therapy achieved lower posttreatment scores on both the Clinical Global Impression scale (magnitude -0.0531; 95% confidence

2010 JAMA Controlled trial quality: predicted high

190. Modeled economic evaluation of alternative strategies to reduce sudden cardiac death among children treated for attention deficit/hyperactivity disorder Full Text available with Trip Pro

with attention deficit and hyperactivity disorder (ADHD). The authors concluded that adding an ECG to screening might be cost-effective, especially when referral to cardiology was based on this alone. The benefits arose mainly from children avoiding competitive sports. The methods were valid and various areas of uncertainty were considered. The authors’ conclusions appear to be robust. Type of economic evaluation Cost-utility analysis Study objective This study examined the cost-effectiveness of screening (...) , before stimulant medication, using an electrocardiogram (ECG), to reduce the risk of sudden cardiac death, in children with attention deficit and hyperactivity disorder (ADHD). Interventions There were three strategies. In strategy one, a history and physical examination were performed and children were referred to cardiology if the findings were abnormal. This was the usual care. In strategy two, a history and physical examination were performed, with an ECG if the findings were normal and referral

2010 NHS Economic Evaluation Database.

191. Duration of effect of oral long-acting stimulant medications for ADHD throughout the day Full Text available with Trip Pro

Duration of effect of oral long-acting stimulant medications for ADHD throughout the day Duration of effect of oral long-acting stimulant medications for ADHD throughout the day Duration of effect of oral long-acting stimulant medications for ADHD throughout the day Brams M, Moon E, Pucci M, Lopez FA CRD summary This review found that most long-acting stimulants conferred benefits in populations with attention-deficit/hyperactivity disorder for up to 12 hours as measured by mathematics tests (...) . Methodological flaws and a lack of information about the quality of the studies mean that the results should be interpreted with some caution and made the reliability of the authors' conclusions unclear. Authors' objectives To determine the duration of effect of long-acting stimulant treatment in patients with attention-deficit hyperactivity disorder (ADHD) using analogue classroom protocols. Searching MEDLINE, BIOSYS and EMBASE were searched to June 2009 for relevant published studies; search terms were

2010 DARE.

192. Neurofeedback training improves ADHD symptoms more than attention skills training Full Text available with Trip Pro

Question Question: Does neurofeedback training produce greater improvements in attention deficit hyperactivity disorder (ADHD) compared with attention skills training? Patients: 102 children (8–12 years old) with DSM-IV ADHD based on a semi-structured clinical interview (CASCAP-D) and the Diagnostic Checklist for Hyperkinetic Disorders/ADHD. Main exclusions : gross neurological or organic disorders; medication or psychotherapy received within 6 weeks of beginning the intervention. Children (...) Neurofeedback training improves ADHD symptoms more than attention skills training Neurofeedback training improves ADHD symptoms more than attention skills training | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional

2010 Evidence-Based Mental Health

193. Conners? Teacher Rating Scale has limited ability to predict DSM-IV ADHD in referred schoolchildren Full Text available with Trip Pro

-IV ADHD in referred schoolchildren Statistics from Altmetric.com Question Question: What is the predictive validity of the revised Conners’ Teacher Rating Scale (CTRS-R) for identifying children with attention deficit hyperactivity disorder (ADHD) in a clinical sample compared with the Telephone Teacher Interview (T TI-IV)? Patients: 1038 children aged 6–12 years referred for assessment of attention, learning and behavioural problems to a pae-diatric clinic (mean age 8.8 years, 75.5% male (...) Conners? Teacher Rating Scale has limited ability to predict DSM-IV ADHD in referred schoolchildren Conners’ Teacher Rating Scale has limited ability to predict DSM-IV ADHD in referred schoolchildren | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal

2010 Evidence-Based Mental Health

194. Management of attention deficit and hyperkinetic disorders in children and young people

make up Attention Deficit Hyperactivity Disorder 1 (ADHD) and Hyperkinetic Disorder 2 (HKD) are the most widely researched in child and adolescent mental health, but there is continuing development of the definition of these disorders and their management. The core symptoms of ADHD and HKD have a significant impact on a child’s development, including social, emotional and cognitive functioning and they are responsible for considerable morbidity and dysfunction for the child or young person (...) physical anomalies is part of an overall physical evaluation. Standardised assessment schedules are available. 4 assessMent3 10 ManageMent of attention deficit and hyperkinetic disorders in children and young people ; Clinical examination of children and young people presenting with ADHD/HKD should include a systems inquiry, details of previous health problems, current drug treatment, and physical examination. vision and hearing should be assessed and formally tested if indicated. 4.8 ancillary

2009 SIGN

195. Evaluating dopamine reward pathway in ADHD: clinical implications. Full Text available with Trip Pro

Evaluating dopamine reward pathway in ADHD: clinical implications. Attention-deficit/hyperactivity disorder (ADHD)--characterized by symptoms of inattention and hyperactivity-impulsivity--is the most prevalent childhood psychiatric disorder that frequently persists into adulthood, and there is increasing evidence of reward-motivation deficits in this disorder.To evaluate biological bases that might underlie a reward/motivation deficit by imaging key components of the brain dopamine reward (...) with ADHD (95% CI, 0.10-0.56; P = .005) and differences in D(2)/D(3) in the hypothalamic region, with controls having a mean of 0.12 vs 0.05 for those with ADHD (95% CI, 0.02-0.12; P = .004). Ratings of attention correlated with D(2)/D(3) in the accumbens (r = 0.35; 95% CI, 0.15-0.52; P = .001), midbrain (r = 0.35; 95% CI, 0.14-0.52; P = .001), caudate (r = 0.32; 95% CI, 0.11-0.50; P = .003), and hypothalamic (r = 0.31; CI, 0.10-0.49; P = .003) regions and with DAT in the midbrain (r = 0.37; 95% CI

2009 JAMA

196. Does Melatonin improve sleep pattern in children with attention deficit hyperactivity disorder?

, Starreveld JS, et al. Melatonin for treatment of sleeping disorders in children with attention deficit/hyperactivity disorder: a preliminary open label study. Eur J Pediatr 2003;162:554–5. Van der Heijden KB, Smits MG, Van Someren EJ, et al. Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insomnia. J Am Acad Child Adolesc Psychiatry 2007;46:233–41. Betancourt-Fursow de Jimenez YM, Jimenez-Leon JC, Jimenez-Betancourt CS. Attention deficit hyperactivity disorder (...) Part Question In [children with ADHD] does [melatonin] improve [sleep pattern]? Clinical Scenario Adam is an 8-year-old boy with attention deficit hyperactivity disorder (ADHD) who you see with his mother in your paediatric outpatient clinic. She explains that life is being made increasingly stressful for the whole family as Adam is having difficulty getting off to sleep. It often takes him several hours to calm down and go to sleep, and the next day he gets angry and seems to be tired all the time

2009 BestBETS

197. Controlled clinical trial of zolpidem for the treatment of insomnia associated with attention-deficit/ hyperactivity disorder in children 6 to 17 years of age (Abstract)

-group study was conducted. Patients underwent stratification according to age (6-11 years [N = 111] or 12-17 years [N = 90]) and were assigned randomly to receive treatment with the study drug or placebo (in a 2:1 ratio). The primary efficacy variable was latency to persistent sleep between weeks 3 and 6. Secondary efficacy variables also were assessed, and behavioral and cognitive components of attention-deficit/hyperactivity disorder were monitored. Safety was assessed on the basis of reports (...) Controlled clinical trial of zolpidem for the treatment of insomnia associated with attention-deficit/ hyperactivity disorder in children 6 to 17 years of age The goal was to evaluate the hypnotic efficacy of zolpidem at 0.25 mg/kg per day (maximum of 10 mg/day), compared with placebo, in children 6 through 17 years of age who were experiencing insomnia associated with attention-deficit/hyperactivity disorder.An 8-week, North American, multicenter, double-blind, placebo-controlled, parallel

2009 EvidenceUpdates Controlled trial quality: predicted high

198. Risperidone for attention-deficit hyperactivity disorder in people with intellectual disabilities. (Abstract)

Risperidone for attention-deficit hyperactivity disorder in people with intellectual disabilities. Attention deficit hyperactivity disorder (ADHD) is increasingly recognised as occurring in people with intellectual disability (ID), although treatment of ADHD in this population has not ben tested widely. Risperidone has been used to treat ADHD in people with ID, although the evidence for its effectiveness is unclear.To examine the effectiveness of risperidone for the treatment of attention (...) deficit hyperactivity disorder in people with intellectual disabilities.In February 2009, MEDLINE, PsycINFO, EMBASE, AMED, ISI Web of Science and WorldCat Dissertations were searched using an extensive list of synonyms for ADHD and ID. CENTRAL, CCDPLP, Current Controlled Trials meta-register (mRCT), CenterWatch, NHS National Research Register, clinicaltrials.gov were searched, pharmaceutical companies and experts in the field were contacted. Reference lists of review articles were examined

2009 Cochrane

199. Amfetamine for attention deficit hyperactivity disorder in people with intellectual disabilities. (Abstract)

Amfetamine for attention deficit hyperactivity disorder in people with intellectual disabilities. Attention-deficit hyperactivity disorder (ADHD) is increasingly recognised as occurring in people with intellectual disability (ID), although treatment of ADHD in this population has not been tested widely. Amfetamine has been used to treat ADHD in people with and without ID, although the evidence for its efficacy in people with ID is unclear.To examine the effectiveness of amfetamine (...) for the treatment of attention deficit hyperactivity disorder in people with intellectual disabilities.MEDLINE, PsycINFO, EMBASE, AMED, ISI Web of Science and WorldCat Dissertations were searched using an extensive list of synonyms for ADHD and ID. CENTRAL, Current Controlled Trials meta-register (mRCT), CenterWatch, NHS National Research Register, clinicaltrials.gov were searched in August 2007. Pharmaceutical companies and experts in the field were contacted. Reference lists of review articles were examined

2009 Cochrane

200. Extended-release medications for children and adolescents with attention-deficit hyperactivity disorder

Extended-release medications for children and adolescents with attention-deficit hyperactivity disorder Attention-deficit hyperactivity disorder (ADHD) affects one in 20 Canadian children, and is associated with unfavourable academic and employment records, high rates of injury and substance abuse, poor interpersonal relationships, poor mental health outcomes and poor quality of life. Medications have been shown to be efficacious in treating ADHD symptoms in controlled trials (...) to all children and youth with ADHD. Key Words: Atomoxetine; Attention-deficit hyperactivity disorder; Effectiveness; Extended-release; Immediate-release; Mixed amphetamine salt; OROS methylphenidate; Quality of life

2009 Canadian Paediatric Society